BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Ebola outbreak
Hantavirus
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Tuesday, June 16, 2026
Home
»
Newsletters
» BioWorld
BioWorld
Feb. 5, 2008
View Archived Issues
Increasing Complexity in Deals Can Be a Blessing or a Curse
Read More
IDM Pops on Paper Showing Survival Benefit for Mifamurtide
Read More
Centocor's Ustekinumab Shows Good Data in Plaque Psoriasis
Read More
Financings Roundup
Read More
Clinic Roundup
Read More
Amgen Unloads 13 Molecules in $1B-plus Deal with Takeda
Amgen Inc. is selling the Japanese rights to 13 molecules, including the FDA-approved colorectal drug Vectibix (panitumumab), to Takeda Pharmaceutical Co. Ltd. in a deal potentially worth more than $1 billion. (BioWorld Today)
Read More
Amira Inks $425M FLAP Inhibitor Deal with GSK
Read More
Other News To Note
Read More
